Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma

Figure 2 Cumulative incidence of hepatocellular carcinoma over 5 years of follow-up in patients treated with nucleos(t)ide analogs vs interferon-based therapy. A: Before propensity score matching: The 5-year cumulative incidence was 25.74% (64/248) in the nucleos(t)ide analogs group and 2.54% (3/120) in the interferon group (P < 0.001, log-rank test); B: After propensity score matching (1:3 matching): The 5-year cumulative incidence was 22.0% (30/145) in the nucleos(t)ide analogs group and 2.94% (2/71) in the interferon group (P < 0.001, log-rank test). Shaded areas represent 95% confidence intervals. HCC: Hepatocellular carcinoma; NAs: Nucleos(t)ide analogs; IFN: Interferon.